Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned

References

• UNAIDS. Global AIDS update 2016, 2016.
   Google Scholar
• UNAIDS. Global AIDS Response Progress Reporting 2015, 2015.
   Google Scholar
• World Health Organization. Global tuberculosis report 2018; 2018.
   Google Scholar
• Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–4655.
   PubMed Web of Science ®Google Scholar
• Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758–1765.
   PubMed Web of Science ®Google Scholar
• Andersen P, Kaufmann SHE. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014;4.
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon B, et al. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Nat Acad Sci USA. 2000;97:13853–13858.
   PubMed Web of Science ®Google Scholar
• Wangoo A, Brown IN, Marshall BG, et al. Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-γ). Clin Exp Immunol. 2000;119:92–98.
   PubMed Web of Science ®Google Scholar
• Fletcher HA. Sleeping beauty and the story of the bacille Calmette-Guérin vaccine. MBio. 2016;7.
   PubMed Web of Science ®Google Scholar
• Lotte A, Wasz-Höckert O, Poisson N, et al. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res. 1984;21:107–193.
   PubMedGoogle Scholar
• Gheorghiu M, Lagrange PH, Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand. 1988;16:15–26.
   PubMedGoogle Scholar
• Matsuo K, Yasutomi Y. Mycobacterium bovis Bacille Calmette-Guérin as a vaccine vector for global infectious disease control. Tuberc Res Treat. 2011;2011:1–9.
   Google Scholar
• Joseph J, Saubi N, Pezzat E, et al. Progress towards an HIV vaccine based on recombinant bacillus Calmette–guérin: failures and challenges. Expert Rev Vaccines. 2006;5:827–838.
   PubMed Web of Science ®Google Scholar
• Melancon-Kaplan J, Hunter SW, McNeil M, et al. Immunological significance of Mycobacterium leprae cell walls. Proc Natl Acad Sci USA. 1988;85:1917–1921.
   PubMed Web of Science ®Google Scholar
• Oiso R, Fujiwara N, Yamagami H, et al. Mycobacterial trehalose 6,6ʹ-dimycolate preferentially induces type 1 helper T cell responses through signal transducer and activator of transcription 4 protein. Microb Pathog. 2005;39:35–43.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Naka T, Doi T, et al. Direct molecular mass determination of trehalose monomycolate from 11 species of mycobacteria by MALDI-TOF mass spectrometry. Microbiol. 2005;151:1443–1452.
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285:732–736.
   PubMed Web of Science ®Google Scholar
• Nunes-Alves C, Booty MG, Carpenter SM, et al. In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol. 2014;12:289–299.
   PubMed Web of Science ®Google Scholar
• Fletcher HA, Schrager L. TB vaccine development and the end TB strategy: importance and current status. Trans R Soc Trop Med Hyg. 2016;110:212–218.
   PubMed Web of Science ®Google Scholar
• Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet. 2008;372:164–175.
   PubMed Web of Science ®Google Scholar
• Tang J, Yam W-C, Chen Z. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis. 2016;98:30–41.
   PubMed Web of Science ®Google Scholar
• O’Shea MK, McShane H. A review of clinical models for the evaluation of human TB vaccines. Hum Vaccines Immuno Ther. 2016;12:1–11.
   Google Scholar
• Skeiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 2006;4:469–476.
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhao A, Cohen C, et al. Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother. 2016;12:1–11.
   Web of Science ®Google Scholar
• Timm J, Lim EM, Gicquel B. Escherichia coli-mycobacteria shuttle vectors for operon and gene fusions to lacZ: the pJEM series. J. Bacteriol. 1994;176:6749–6753.
   Google Scholar
• Snapper SB, Melton RE, Mustafa S, et al. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol. 1990;4:1911–1919.
   PubMed Web of Science ®Google Scholar
• Snapper SB, Lugosi L, Jekkel A, et al. Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci USA. 1988;85:6987–6991.
   PubMed Web of Science ®Google Scholar
• Bastos RG, Borsuk S, Seixas FK, et al. Recombinant Mycobacterium bovis BCG. Vaccine. 2009;27:6495–6503.
   PubMed Web of Science ®Google Scholar
• Goto Y, Taniguchi H, Udou T, et al. Development of a new host vector system in mycobacteria. FEMS Microbiol Lett. 1991;67:277–282.
   PubMedGoogle Scholar
• Stover CK, de la Cruz VF, Fuerst TR, et al. New use of BCG for recombinant vaccines. Nature. 1991;351:456–460.
   PubMed Web of Science ®Google Scholar
• Méderlé I, Bourguin I, Ensergueix D, et al. Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun. 2002;70:303–314.
   PubMed Web of Science ®Google Scholar
• Labidi A, David HL, Roulland-Dussoix D. Restriction endonuclease mapping and cloning of Mycobacterium fortuitum var. fortuitum plasmid pAL5000. Ann l’Institut Pasteur Microbiologie. 1985;136B:209–215.
   PubMedGoogle Scholar
• Lee H, Kim BJ, Kim BR, et al. The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T. PLoS One. 2015;10:e0122897.
   Web of Science ®Google Scholar
• Kim B-J, Gong J-R, Kim G-N, et al. Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing human immunodeficiency virus type I gag can induce enhanced virus-specific immune responses. Sci Rep. 2017;7:44776.
   PubMed Web of Science ®Google Scholar
• Lugosi L, Jacobs WR, Bloom BR. Genetic transformation of BCG. Tubercle. 1989;70:159–170.
   PubMedGoogle Scholar
• Yu J-S, Peacock JW, Vanleeuwen S, et al. Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. Clin Vaccine Immunol. 2006;13:1204–1211.
   PubMed Web of Science ®Google Scholar
• Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature. 1991;351:479–482.
   PubMed Web of Science ®Google Scholar
• Joseph J, Fernández-Lloris R, Pezzat E, et al. Molecular characterization of heterologous HIV-1gp120 gene expression disruption in Mycobacterium bovis BCG host strain: a critical issue for engineering Mycobacterial based-vaccine vectors. J Biomed Biotechnol 2010. 2010.
   Google Scholar
• Saubi N, Gea-Mallorquí E, Ferrer P, et al. Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG. Mol Ther Methods Clin Dev. 2014;1:14017.
   PubMed Web of Science ®Google Scholar
• Streit JA, Recker TJ, Donelson JE, et al. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol. 2000;94:33–41.
   PubMed Web of Science ®Google Scholar
• Chapman R, Chege G, Shephard E, et al. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res. 2010;8:282–298.
   PubMed Web of Science ®Google Scholar
• Dennehy M, Bourn W, Steele D, et al. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. Vaccine. 2007;25:3646–3657.
   PubMed Web of Science ®Google Scholar
• Movahedzadeh F, Bitter W. Ins and outs of mycobacterial plasmids. Methods Mol Biol. 2008;465:217–228.
   Google Scholar
• Pashley CA, Parish T. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol Lett. 2003;229:211–215.
   PubMed Web of Science ®Google Scholar
• Lewis JA, Hatfull GF. Identification and characterization of mycobacteriophage L5 excisionase, Mol. Microbiol. 2000;35:350–360.
   Web of Science ®Google Scholar
• Bhatt A, Jacobs WR. Gene essentiality testing in Mycobacterium smegmatis using specialized transduction. Methods Mol Biol. 2008;465:325–336.
   Google Scholar
• Dieci G, Giuliodori S, Catellani M, et al. Intragenic promoter adaptation and facilitated RNA polymerase III recycling in the transcription of SCR1, the 7SL RNA gene of Saccharomyces cerevisiae. J. Biol Chem. 2002;277:6903–6914.
   PubMed Web of Science ®Google Scholar
• Newton-Foot M, Gey Van Pittius NC. The complex architecture of mycobacterial promoters. Tuberculosis. 2013;93:60–74.
   PubMed Web of Science ®Google Scholar
• Kanno AI, Goulart C, Rofatto HK, et al. New recombinant Mycobacterium bovis BCG expression vectors: improving genetic control over mycobacterial promoters. Appl Environ Microbiol. 2016.
   PubMed Web of Science ®Google Scholar
• Batoni G, Maisetta G, Florio W, et al. Analysis of the Mycobacterium bovis hsp60 promoter activity in recombinant Mycobacterium avium. FEMS Microbiol Lett. 1998;169:117–124.
   PubMed Web of Science ®Google Scholar
• Leung NJ, Aldovini A, Young R, et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology. 2000;268:94–103.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Hashimoto A, Toida I, et al. Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol. 2002;105:326–331.
   PubMed Web of Science ®Google Scholar
• Stover CK, Bansal GP, Hanson MS, et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med. 1993;178:197–209.
   PubMed Web of Science ®Google Scholar
• Langermann S, Palaszynski SR, Burlein JE, et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med. 1994;180:2277–2286.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Matsuo K, Hamatake M, et al. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guerin expressing human immunodeficiency virus type 1 Gag. J Virol. 2005;79:8716–8723.
   PubMed Web of Science ®Google Scholar
• MacHowski EE, McAdam RA, Derbyshire KM, et al. Construction and application of mycobacterial reporter transposons. Gene. 2000;253:67–75.
   PubMed Web of Science ®Google Scholar
• Parish T, Liu J, Nikaido H, et al. A Mycobacterium smegmatis mutant with a defective inositol monophosphate phosphatase gene homolog has altered cell envelope permeability. J Bacteriol. 1997;179:7827–7833.
   PubMed Web of Science ®Google Scholar
• Movahedzadeh F, Frita R, Gutka HJ. A two-step strategy for the complementation of M. tuberculosis mutants. Genet Mol Biol. 2011;34:286–289.
   PubMed Web of Science ®Google Scholar
• Triccas JA, Parish T, Britton WJ, et al. An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis. FEMS Microbiol Lett. 1998;167:151–156.
   PubMed Web of Science ®Google Scholar
• Brown AC, Parish T. Instability of the acetamide-inducible expression vector pJAM2 in Mycobacterium tuberculosis. Plasmid. 2006;55:81–86.
   PubMed Web of Science ®Google Scholar
• Manabe YC, Chen JM, Ko CG, et al. Conditional sigma factor expression, using the inducible acetamidase promoter, reveals that the Mycobacterium tuberculosis sigF gene modulates expression of the 16-kilodalton alpha-crystallin homologue. J. Bacteriol. 1999;181:7629–7633.
   PubMed Web of Science ®Google Scholar
• Carroll P, Niranjala Muttucumaru DG, Parish T. Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol. 2005;71:3077–3084.
   PubMed Web of Science ®Google Scholar
• Via LE, Curcic R, Mudd MH, et al. Elements of signal transduction in Mycobacterium tuberculosis: in vitro phosphorylation and in vivo expression of the response regulator MtrA. J Bacteriol. 1996;178:3314–3321.
   PubMed Web of Science ®Google Scholar
• Himmelrich H, Lo-Man R, Winter N, et al. Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malE. Vaccine. 2000;18:2636–2647.
   PubMed Web of Science ®Google Scholar
• Murray A, Winter N, Lagranderie M, et al. Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol Microbiol. 1992;6:3331–3342.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Yamaguchi R, Yamazaki A, et al. Establishment of a foreign antigen secretion system in mycobacteria. Infect Immun. 1990;58:4049–4054.
   PubMed Web of Science ®Google Scholar
• Winter N, Lagranderie M, Rauzier J, et al. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene. 1991;109:47–54.
   PubMed Web of Science ®Google Scholar
• Al-Zarouni M, Dale JW. Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis. 2002;82:283–291.
   PubMed Web of Science ®Google Scholar
• Bastos RG, Dellagostin OA, Barletta RG, et al. Construction and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M protein of porcine reproductive respiratory syndrome virus. Vaccine. 2002;21:21–29.
   PubMed Web of Science ®Google Scholar
• Mahant A, Saubi N, Eto Y, et al. Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. Hum Vaccin Immunother. 2017;13:1798–1810.
   PubMed Web of Science ®Google Scholar
• Oliveira TL, Rizzi C, Dellagostin OA. Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genes. Appl Microbiol Biotechnol. 2017;101:6865–6877.
   PubMed Web of Science ®Google Scholar
• Da Costa AC, Nogueira SV, Kipnis A, et al. Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol. 2014;5:152.
   PubMed Web of Science ®Google Scholar
• Ohara N, Matsuoka M, Nomaguchi H, et al. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant bacillus Calmette-Guérin over-producing three putative protective antigen candidates. Vaccine. 2001;19:1906–1910.
   PubMed Web of Science ®Google Scholar
• Seixas FK, Da Silva ÉF, Hartwig DD, et al. Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine. 2007;26:88–95.
   PubMed Web of Science ®Google Scholar
• Trovato M, D’Apice L, Prisco A, et al. HIV vaccination: a roadmap among advancements and concerns. Int J Mol Sci. 2018;19.
   Web of Science ®Google Scholar
• de Taeye SW, Moore JP, Sanders RW. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol. 2016;37:221–232.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155:531–539.
   PubMed Web of Science ®Google Scholar
• Ondondo B, Murakoshi H, Clutton G, et al. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. Mol Ther. 2016;24:832–842.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, D’Couto HT, Barouch DH. New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016;41:39–46.
   PubMed Web of Science ®Google Scholar
• Kameoka M, Nishino Y, Matsuo K, et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine. 1994;12:153–158.
   PubMed Web of Science ®Google Scholar
• Lim EM, Lagranderie M, Le Grand R, et al. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res Hum Retroviruses. 1997;13:1573–1581.
   PubMed Web of Science ®Google Scholar
• Honda M, Matsuo K, Nakasone T, et al. Protective immune-responses induced by secretion of a chimeric soluble-protein from a recombinant Mycobacterium-bovis bacillus-Calmette-Guerin vector candidate vaccine for human-immunodeficiency-virus type-1 in small animals. Proc Natl Acad Sci USA. 1995;92:10693–10697.
   PubMed Web of Science ®Google Scholar
• Andersson GE, Sharp PM. Codon usage in the Mycobacterium tuberculosis complex. Microbiol. 1996;142(4):915–925.
   PubMedGoogle Scholar
• Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, et al. Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice. Immunol Invest. 2009;38:762–779.
   PubMed Web of Science ®Google Scholar
• Skogman G, Nilsson J, Gustafsson P. The use of a partition locus to increase stability of tryptophan-operon-bearing plasmids in Escherichia coli. Gene. 1983;23:105–115.
   PubMed Web of Science ®Google Scholar
• Maguin E, Duwat P, Hege T, et al. New thermosensitive plasmid for gram-positive bacteria. J Bacteriol. 1992;174:5633–5638.
   PubMed Web of Science ®Google Scholar
• Fabre EE, Bigey P, Beuzard Y, et al. Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment. Genet Vaccines Ther. 2008;6:10.
   PubMedGoogle Scholar
• Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008;16:972–978.
   PubMed Web of Science ®Google Scholar
• Maulik N. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia. Curr Opin Investig Drugs. 2009;10:259–268.
   PubMedGoogle Scholar
• Saubi N, Mbewe-Mvula A, Gea-Mallorqui E, et al. Pre-clinical development of BCG.HIVACAT, an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS One. 2012;7:e42559.
   PubMed Web of Science ®Google Scholar
• Williams SG, Cranenburgh RM, Weiss AM, et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res. 1998;26:2120–2124.
   PubMed Web of Science ®Google Scholar
• Cobra biologics and pharmaceutical services - cobra bio. Available from: http://www.cobrabio.com/. Date accessed: 2017-09-12
   Google Scholar
• Cascioferro A, Boldrin F, Serafini A, et al. Xer site-specific recombination, an efficient tool to introduce unmarked deletions into mycobacteria. Appl Environ Microbiol. 2010;76:5312–5316.
   PubMed Web of Science ®Google Scholar
• Chujoh Y, Matsuo K, Yoshizaki H, et al. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B??? strains by recombinant Mycobacterium bovis BCG-based candidate vaccine. Vaccine. 2001;20:797–804.
   PubMed Web of Science ®Google Scholar
• Hiroi T, Goto H, Someya K, et al. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol. 2001;167:5862–5867.
   PubMed Web of Science ®Google Scholar
• Sato H, Jing C, Isshiki M, et al. Immunogenicity and safety of the vaccinia virus LC16m8? Vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol. Vaccine. 2013;31:3549–3557.
   PubMed Web of Science ®Google Scholar
• Hopkins R, Bridgeman A, Joseph J, et al. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One. 2011;6:e20067.
   PubMed Web of Science ®Google Scholar
• Hopkins R, Bridgeman A, Bourne C, et al. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol. 2011;41:3542–3552.
   PubMed Web of Science ®Google Scholar
• Chapman R, Stutz H, Jacobs W, et al. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a Robust T cell response in mice. PLoS One. 2013;8.
   Web of Science ®Google Scholar
• Hart BE, Asrican R, Lim S-Y, et al. Stable expression of lentiviral antigens by quality-controlled recombinant Mycobacterium bovis BCG vectors. Clin Vaccine Immunol. 2015;22:726–741.
   PubMed Web of Science ®Google Scholar
• Yu J-S, Peacock JW, Jacobs WR Jr., et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin Vaccine Immunol. 2007;14:886.
   PubMed Web of Science ®Google Scholar
• Aravindhan V, Narayanan S, Gautham N, et al. T-h-2 immunity and CD3+CD45RBlow-activated T cells in mice immunized with recombinant bacillus Calmette-Guérin expressing HIV-1 principal neutralizing determinant epitope. FEMS Immunol Med Microbiol. 2006;47:45–55.
   PubMedGoogle Scholar
• Panas MW, Sixsmith JD, White K, et al. Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses. Infect Immun. 2014;82:5317–5326.
   PubMed Web of Science ®Google Scholar
• Chapman R, Shephard E, Stutz H, et al. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One. 2012;7:e32769.
   PubMed Web of Science ®Google Scholar
• Chapman R, Bourn WR, Shephard E, et al. The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. PLoS One. 2014.
   Google Scholar
• Venkataswamy MM, Ng TW, Kharkwal SS, et al. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One. 2014;9:e108383.
   PubMed Web of Science ®Google Scholar
• Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, et al. Enhancement of cell-mediated immune response in mice by whole HIV-1. Southeast Asian J Trop Med Public Health. 2009;40:113–122.
   Web of Science ®Google Scholar
• Promkhatkaew D, Matsuo K, Pinyosukhee N, et al. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization. Southeast Asian J Trop Med Public Health. 2009;40:273–281.
   Google Scholar
• Saubi N, Im E-J, Fernández-Lloris R, et al. Newborn mice vaccination with BCG.HIVA 222 + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol 2011;2011:1–11.
   Google Scholar
• Jongwe TI, Chapman R, Douglass N, et al. HIV-1 subtype C mosaic Gag expressed by BCG and MVA elicits persistent effector T cell responses in a prime-boost regimen in mice. PLoS One. 2016;11:e0159141.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Matsuo K, Honda M. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs. Clin Immunol. 2006;119:67–78.
   PubMed Web of Science ®Google Scholar
• Kawahara M. Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFNγ response, even at three years after immunization. Clin Immunol. 2008;129:492–498.
   PubMed Web of Science ®Google Scholar
• Ami Y, Izumi Y, Matsuo K, et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol. 2005;79:12871–12879.
   PubMed Web of Science ®Google Scholar
• Cayabyab MJ, Korioth-Schmitz B, Sun Y, et al. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol. 2009;83:5505–5513.
   PubMed Web of Science ®Google Scholar
• Rosario M, Hopkins R, Fulkerson J, et al. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in Rhesus Macaques. J Virol. 2010;84:5898–5908.
   PubMed Web of Science ®Google Scholar
• Rosario M, Fulkerson J, Soneji S, et al. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate Rhesus Macaques. J Virol. 2010;84:7815–7821.
   PubMed Web of Science ®Google Scholar
• Jensen K, Ranganathan UDK, Van Rompay KKA, et al. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vaccine Immunol. 2012;19:1170–1181.
   PubMed Web of Science ®Google Scholar
• Jensen K, Dela Pena MG, Wilson RL, et al. A neonatal oral Mycobacterium tuberculosis-SIV prime/intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques. Trials Vaccinol. 2013;2:53–63.
   PubMedGoogle Scholar
• Chege GK, Burgers WA, Stutz H, et al. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol. 2013;87:5151–5160.
   PubMed Web of Science ®Google Scholar
• Martins MA, Wilson NA, Piaskowski SM, et al. Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol. 2014;88:7493–7516.
   PubMed Web of Science ®Google Scholar
• Sixsmith JD, Panas MW, Lee S, et al. Recombinant Mycobacterium bovis bacillus calmette-guerin vectors prime for strong cellular responses to simian immunodeficiency virus gag in Rhesus Macaques. Clin Vaccine Immunol. 2014;21:1385–1395.
   PubMed Web of Science ®Google Scholar
• Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther. 2009;9:1279–1287.
   PubMed Web of Science ®Google Scholar
• Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27:4468–4474.
   PubMed Web of Science ®Google Scholar
• Cayabyab MJ, Hovav A-H, Hsu T, et al. Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol. 2006;80:1645–1652.
   PubMed Web of Science ®Google Scholar
• Sixsmith JD, Panas MW, Lee S, et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in Rhesus Macaques. Clin Vaccine Immunol. 2014;21:1385–1395.
   PubMed Web of Science ®Google Scholar
• Korioth-Schmitz B, Perley CC, Sixsmith JD, et al. Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity. Vaccine. 2015;33:5715–5722.
   PubMed Web of Science ®Google Scholar
• Chaparas SD, Maloney CJ, Hedrick SR. Specificity of tuberculins and antigens from various species of mycobacteria. Am Rev Respir Dis. 1970;101:74–83.
   PubMed Web of Science ®Google Scholar
• Harboe M, Mshana RN, Closs O, et al. Cross-reactions between mycobacteria. II. Crossed immunoelectrophoretic analysis of soluble antigens of BCG and comparison with other mycobacteria. Scand J Immunol. 1979;9:115–124.
   PubMed Web of Science ®Google Scholar
• von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis. 2001;5:1122–1128.
   PubMed Web of Science ®Google Scholar
• von Reyn CF, Williams DE, Horsburgh CR, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis. 1998;177:730–736.
   PubMed Web of Science ®Google Scholar
• Black GF, Dockrell HM, Crampin AC, et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis. 2001;184:322–329.
   PubMed Web of Science ®Google Scholar
• Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet (London, England). 2002;359:1393–1401.
   PubMed Web of Science ®Google Scholar
• Weir RE, Fine PEM, Nazareth B, et al. Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria. Clin Exp Immunol. 2003;134:285–294.
   PubMed Web of Science ®Google Scholar
• Floyd S, Pönnighaus JM, Bliss L, et al. Kinetics of delayed-type hypersensitivity to tuberculin induced by bacille Calmette-Guérin vaccination in northern Malawi. J Infect Dis. 2002;186:807–814.
   PubMed Web of Science ®Google Scholar
• Black GF, Fine PEM, Warndorff DK, et al. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi. Int J Tuberc Lung Dis. 2001;5:664–672.
   PubMed Web of Science ®Google Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun. 2002;70:672–678.
   PubMed Web of Science ®Google Scholar
• de Lisle GW, Wards BJ, Buddle BM, et al. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis. 2005;85:73–79.
   PubMed Web of Science ®Google Scholar
• World Health Organization. BCG vaccine: WHO position paper, February 2018 – recommendations. Vaccine. 2018;36:3408–3410.
   PubMed Web of Science ®Google Scholar
• Faurholt-Jepsen D, Range N, PrayGod G, et al. BCG protects against tuberculosis irrespective of HIV status: a matched case-control study in Mwanza, Tanzania: table 1. Thorax. 2013;68:288–289.
   PubMed Web of Science ®Google Scholar
• Bhat GJ, Diwan VK, Chintu C, et al. HIV, BCG and TB in children: a case control study in Lusaka, Zambia. J Trop Pediatr. 1993;39:219–223.
   PubMed Web of Science ®Google Scholar
• Van-Dunem JC, Rodrigues LC, Alencar LCA, et al. Effectiveness of the first dose of BCG against tuberculosis among HIV-Infected, Predominantly Immunodeficient Children. Biomed Res Int 2015. 2015;2015:1–10.
   Google Scholar
• Roth A, Gustafson P, Nhaga A, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol. 2005;34:540–547.
   PubMed Web of Science ®Google Scholar
• Post CL, Victora CG, Valente JG, et al. Prognostic factors of hospital mortality from diarrhea or pneumonia in infants younger than 1 year old. A case-control study. Rev Saude Publica. 1992;26:369–378.
   PubMed Web of Science ®Google Scholar
• Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9:355–361.
   PubMed Web of Science ®Google Scholar
• van der Meer JWM, Joosten LAB, Riksen N, et al. Trained immunity: a smart way to enhance innate immune defence. Mol Immunol. 2015;68:40–44.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci. 2012;109:17537–17542.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014;155:213–219.
   PubMed Web of Science ®Google Scholar
• Jensen K, Nabi R, Van Rompay KKA, et al. Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant Rhesus Macaques. J Virol. 2016;90:7285–7302.
   PubMed Web of Science ®Google Scholar
• Jensen K, Dela Pena-Ponce MG, Piatak M, et al. Balancing Trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated mycobacterium tuberculosis or Mycobacterium bovis BCG vaccine. Clin Vaccine Immunol. 2017;24:e00360–16.
   PubMed Web of Science ®Google Scholar
• Thayil SM, Ho Y-C, Bollinger RC, et al. Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathway. PLoS One. 2012;7:e41093.
   PubMedGoogle Scholar
• Rampini SK, Selchow P, Keller C, et al. LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiol. 2008;154:2991–3001.
   PubMed Web of Science ®Google Scholar
• Sander P, Rezwan M, Walker B, et al. Lipoprotein processing is required for virulence of Mycobacterium tuberculosis. Mol Microbiol. 2004;52:1543–1552.
   PubMed Web of Science ®Google Scholar
• Seshadri C, Turner MT, Lewinsohn DM, et al. Lipoproteins are major targets of the polyclonal human T cell response to Mycobacterium tuberculosis. J Immunol. 2013;190:278–284.
   PubMed Web of Science ®Google Scholar
• Behr MA. BCG–different strains, different vaccines? Lancet Infect Dis. 2002;2:86–92.
   PubMed Web of Science ®Google Scholar
• Gheorghiu M, Lagrange PH, Lagranderie M, et al. The effects of dispersed or surface grown cultures, manufacture and control methods on BCG standardization. Dev Biol Stand. 1986;58(Pt A):191–205.
   PubMedGoogle Scholar
• Champlin R, Hunter RL. Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J Immunol. 1975;114:76–80.
   PubMed Web of Science ®Google Scholar
• van Faassen H, Dudani R, Krishnan L, et al. Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes. J Immunol. 2004;172:3491–3500.
   PubMed Web of Science ®Google Scholar
• van Faassen H, Saldanha M, Gilbertson D, et al. Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol. 2005;174:5341–5350.
   PubMed Web of Science ®Google Scholar
• Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009;15:293–299.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Weekly epidemiological record Relevé épidémiologique hebdomadaire; 2007;82:181–196.
   Google Scholar
• Joosten SA, Sullivan LC, Ottenhoff THM. Characteristics of HLA-E restricted T-cell responses and their role in infectious diseases. J Immunol Res. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999;10:661–671.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Blazevic A, Selimovic A, et al. Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-naïve adults: a randomized, active-controlled, first-in-human phase 1 trial. EBioMedicine. 2016;7:278–286.
   PubMed Web of Science ®Google Scholar